Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 11/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873169 | 0.85 | MAPKAPK2 (0.49) | SIRT1ABCB1ABCG2MAPKAPK2SIRT2 | |
| SCHEMBL3874320 | 0.82 | MAPKAPK2 (0.52) | SIRT1ABCB1ABCG2MAPKAPK2SIRT2 | |
| SCHEMBL3886844 | 0.81 | SIRT1 (0.44) | SIRT1ABCB1ABCG2MAPKAPK2SIRT2 | |
| SCHEMBL3882047 | 0.78 | SIRT1 (0.42) | SIRT1MAPKAPK2SIRT2MAPTKIF11 | |
| SCHEMBL3874880 | 0.76 | MAPKAPK2 (0.47) | SIRT1ABCB1ABCG2MAPKAPK2SIRT2 | |
| SCHEMBL3875937 | 0.72 | SIRT1 (0.62) | SIRT1MAPKAPK2SIRT2 | |
| SCHEMBL6239882 | 0.68 | MAPKAPK2 (0.74) | SIRT1ABCG2MAPKAPK2MAPT | |
| SCHEMBL7443250 | 0.67 | BAZ2B (0.54) | MAPTLMNA | |
| SCHEMBL3875060 | 0.67 | TRPM8 (0.45) | ABCB1ABCG2MAPTKIF11LMNA | |
| SCHEMBL7981942 | 0.63 | PRCP (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | claimed |
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | claimed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | claimed |
| EP-1919475-A1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | claimed |
| WO-2007028460-A1 | TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-15 | — | — | WO | claimed |
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | disclosed |
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
| EP-1919475-A1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007028460-A1 | TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | HTR6, HTR5A, HTR1B | SIRT1 1156/4885ABCB1 645/4885ABCG2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.